(NASDAQ: TYRA) Tyra Biosciences's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 58.13%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.77%.
Tyra Biosciences's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast TYRA's revenue for 2027 to be $1,036,970,805, with the lowest TYRA revenue forecast at $1,036,970,805, and the highest TYRA revenue forecast at $1,036,970,805. On average, 2 Wall Street analysts forecast TYRA's revenue for 2028 to be $7,166,000,042, with the lowest TYRA revenue forecast at $5,011,493,778, and the highest TYRA revenue forecast at $9,320,506,307.
In 2029, TYRA is forecast to generate $20,086,124,493 in revenue, with the lowest revenue forecast at $11,433,799,630 and the highest revenue forecast at $28,738,449,356.